AlzeCure Pharma AB (FRA:AC6) ROCE %: -355.89% (As of Mar. 2026)


FRA:AC6 AlzeCure Pharma AB FRA:AC6
33 GF Score
Price €0.53
! 1 Warning Sign
View Full Analysis

What is AlzeCure Pharma AB ROCE %?

AlzeCure Pharma AB FRA:AC6 -6.97% 33 ROCE % is -355.89% as of Mar. 2026. GuruFocus rates FRA:AC6 with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AlzeCure Pharma AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -355.89%.

AlzeCure Pharma AB  (FRA:AC6) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AlzeCure Pharma AB ROCE % Related Terms

AlzeCure Pharma AB ROCE % Historical Data

* Premium members only.

The historical data trend for AlzeCure Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlzeCure Pharma AB ROCE % Chart

AlzeCure Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -107.45 -117.44 -82.70 -119.08 -149.08

AlzeCure Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -181.33 -346.16 -133.26 -160.02 -355.89
FRA:AC6
33GF Score
AlzeCure Pharma AB FRA:AC6
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AlzeCure Pharma AB ROCE % Calculation

AlzeCure Pharma AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-4.356/( ( (3.413 - 0.83) + (5.426 - 2.165) )/ 2 )
=-4.356/( (2.583+3.261)/ 2 )
=-4.356/2.922
=-149.08 %

AlzeCure Pharma AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-8.036/( ( (5.426 - 2.165) + (3.788 - 2.533) )/ 2 )
=-8.036/( ( 3.261 + 1.255 )/ 2 )
=-8.036/2.258
=-355.89 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -355.89% mean?
AlzeCure Pharma AB (FRA:AC6) has a ROCE % of -355.89% as of Mar. 2026.
Is AlzeCure Pharma AB's ROCE % too high?
AlzeCure Pharma AB's current ROCE % is -355.89%. Overall, AlzeCure Pharma AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's ROCE % compare to VRTX and REGN?
AlzeCure Pharma AB's ROCE % of -355.89% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. AlzeCure Pharma AB's current ROCE % is -355.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (FRA:AC6) has a current ROCE % of -355.89%. The current ROCE % is -355.89%. AlzeCure Pharma AB's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For AlzeCure Pharma AB (FRA:AC6), the current ROCE % is -355.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AlzeCure Pharma AB Business Description

Other Exchanges ALZCUR:Sweden
Address Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
33GF Score

Get the complete analysis for FRA:AC6

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price